Featured Research

from universities, journals, and other organizations

United States medicaid beneficiaries not adequately following lupus treatment plans

Date:
October 27, 2013
Source:
American College of Rheumatology (ACR)
Summary:
Medicaid beneficiaries with lupus are not adequately following their treatment plans, and this puts them at risk for poor health outcomes, according to new research. For most lupus medications, fewer than one in three beneficiaries were found to be adherent.

Medicaid beneficiaries with lupus are not adequately following their treatment plans, and this puts them at risk for poor health outcomes, according to research presented this week at the American College of Rheumatology Annual Meeting in San Diego. For most lupus medications, fewer than one in three beneficiaries were found to be adherent.

Systemic lupus erythematosus, also called SLE or lupus, is a chronic inflammatory disease that can affect the skin, joints, kidneys, lungs, nervous system, and/or other organs of the body. The most common symptoms include skin rashes and arthritis, often accompanied by fatigue and fever. Lupus occurs mostly in women, typically developing in individuals in their twenties and thirties -- prime child-bearing age.

Immunosuppressive and anti-malarial drugs are the cornerstones of treatment for patients with lupus, and these treatments have been shown to improve patient outcomes by reducing disease activity, joint and organ damage, and death. Researchers from The University of California and Brigham and Women's Hospital in Boston recently examined adherence to these medications in a nationwide study of Medicaid beneficiaries with lupus.

"This study is important because it is the first time we have national data about a very vulnerable group of patients, Medicaid beneficiaries with lupus, and our study paints a sobering picture of medication adherence in this group of patients" explains Jinoos Yazdany, MD, MPH; associate clinical director, Lupus Clinic, University of California, San Francisco Medical Center; and lead investigator in the study.

Dr. Yazdany's team reviewed Medicaid records of lupus patients who had received either an immunosuppressive -- e.g., oral cyclophosphamide (Cytoxan®) mycophenolate mofetil (CellCept®) or leflunomide (Arava®), methotrexate (Trexall®; Rheumatrex®), or tacrolimus (Prograf®) -- or an anti- malarial -- e.g., hydroxychloroquine (Plaquenil®) -- drug through an outpatient pharmacy between the years of 2000 and 2006. The researchers used pharmacy claims to assess adherence to these treatments by noting the amount of medication dispensed over a six-month period following the initial prescription.

"We observed each patient over a fixed interval of 180 days to ensure all patients were studied for the same time period," explains Dr. Yazdany, whose team also took sociodemographic characteristics and geographic region into consideration when looking at adherence. Additionally, Dr. Yazdany's team made a point to examine the number of patients considered at least 80 percent adherent to their treatment plans.

"Adherence was very low for all drugs. We were surprised to find that less than one in three patients were adherent to most of the drugs we examined. What clinicians need to realize is that a majority of this vulnerable population is not taking their lupus medication as prescribed, putting them at risk for poor health outcomes," says Dr. Yazdany.

The Medicaid records of 23,187 people with lupus who were taking at least one immunosuppressive or anti-malarial drug were included in the study. The average age of those reviewed was 38, and the majority (94 percent) were females; however, the racial and ethnic makeup of the group was diverse (40 percent African American, 34 percent Caucasian, 16 percent Hispanic, five percent Asian, five percent Other, and one percent Native American). And, most patients resided in the Southern United States.

Patients' adherence ranged from 31.1 percent for the immunosuppressant tacrolimus to 56.9 percent for the anti-malrial hydroxychloroquine. Across all medications, researchers found African Americans had lower adherence when compared to Caucasians. For many medications, Asians had higher adherence than Caucasians. For example, for hydroxychloroquine, adherence was significantly higher among Asians, and lower in African Americans, Hispanics, and Native Americans when compared to Caucasians. The researchers note that these racial/ethnic differences require further investigation. A more complete analysis to better understand additional factors is planned.

Finally, Dr. Yazdany's team found adherence to be the lowest for patients residing in the Midwest, and highest for those in the Northeast.

The smallest group of all: those who were considered adherent at least 80 percent of the time.

"This study tells us that working with lupus patients to improve adherence is central to improving health outcomes," explains Dr. Yazdany "It is important for patients to understand the life-saving nature of these medications and to communicate with their doctors if they have concerns about their medications."

The American College of Rheumatology is an international professional medical society that represents more than 9,000 rheumatologists and rheumatology health professionals around the world. Its mission is to advance rheumatology. The ACR/ARHP Annual Meeting is the premier meeting in rheumatology. For more information about the meeting, visit http://www.acrannualmeeting.org/ or join the conversation on Twitter by using the official hashtag: #ACR13.


Story Source:

The above story is based on materials provided by American College of Rheumatology (ACR). Note: Materials may be edited for content and length.


Cite This Page:

American College of Rheumatology (ACR). "United States medicaid beneficiaries not adequately following lupus treatment plans." ScienceDaily. ScienceDaily, 27 October 2013. <www.sciencedaily.com/releases/2013/10/131027123049.htm>.
American College of Rheumatology (ACR). (2013, October 27). United States medicaid beneficiaries not adequately following lupus treatment plans. ScienceDaily. Retrieved October 22, 2014 from www.sciencedaily.com/releases/2013/10/131027123049.htm
American College of Rheumatology (ACR). "United States medicaid beneficiaries not adequately following lupus treatment plans." ScienceDaily. www.sciencedaily.com/releases/2013/10/131027123049.htm (accessed October 22, 2014).

Share This



More Health & Medicine News

Wednesday, October 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

CDC Revamps Ebola Guidelines After Criticism

CDC Revamps Ebola Guidelines After Criticism

Newsy (Oct. 21, 2014) — The Centers for Disease Control and Prevention have issued new protocols for healthcare workers interacting with Ebola patients. Video provided by Newsy
Powered by NewsLook.com
WHO: Ebola Vaccine Trials to Start a in January

WHO: Ebola Vaccine Trials to Start a in January

AP (Oct. 21, 2014) — Tens of thousands of doses of experimental Ebola vaccines could be available for "real-world" testing in West Africa as soon as January as long as they are deemed safe in soon to start trials, the World Health Organization said Tuesday. (Oct. 21) Video provided by AP
Powered by NewsLook.com
First-Of-Its-Kind Treatment Gives Man Ability To Walk Again

First-Of-Its-Kind Treatment Gives Man Ability To Walk Again

Newsy (Oct. 21, 2014) — A medical team has for the first time given a man the ability to walk again after transplanting cells from his brain onto his severed spinal cord. Video provided by Newsy
Powered by NewsLook.com
CDC Issues New Ebola Guidelines for Health Workers

CDC Issues New Ebola Guidelines for Health Workers

Reuters - US Online Video (Oct. 21, 2014) — The U.S. Centers for Disease Control and Prevention has set up new guidelines for health workers taking care of patients infected with Ebola. Linda So reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins